Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies.
Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-ABL-induced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic molecular pathways and their pharmacological inhibition may interfere with immune functions. Rational combinations of molecularly targeted and immunological strategies may provide a means for more effective cancer targeting.
Department of Pediatric Hematology and Oncology; University Children's Hospital Muenster; Muenster, Germany.
Claudia
C
Rossig